Topic: cancer development
Inhibiting the PHLPP2 phosphatase enzyme could be an efficient way to suppress MYC-driven prostate cancer, scientists found.
Roche has penned a deal with DART player MacroGenics.
Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO.
Endometrial cancer is becoming both more prevalent and more deadly, yet there are still no good screening methods to catch the disease in its earliest stages. Scientists at the Icahn School of Medicine at Mount Sinai in New York are working on a solution, and it lies in detecting genetic mutations in the lining of the uterus.